Eighth EUCAST Steering Committee Meeting

Summary of minutes of meeting held in Munich, Germany, 7-8 September 2004

Attending
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Gunnar Kahlmeter GK Chairperson Sweden
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Dr Johan W. Mouton JM CRG The Netherlands
Dr Ingrid Nilsson-Ehle IN-E SRGA Sweden
Prof Arne Rodloff AR DIN Germany
Prof Claude-James Soussy C-JS CA-SFM France
Dr Martin Steinbakk MS NWGA Norway
Dr Olga Stetsiouk OS EUCAST Russia
Dr Francisco Soriano FS EUCAST Spain

Apologies
Dr Anders Österlund AO SRGA Sweden
Dr Fred Goldstein FG SFM France

Attending for daptomycin presentation from Chiron (minute 2)
Jeff Alder JA Vice President, Drug Discovery and Evaluation
Paul Derbyshire PD Orphix Consulting, Consultant for Chiron
Dave Griffin DG Director, Microbiology & Clinical Development Europe
Grace Thorne GT Senior Director, Clinical Microbiology

Attending for tigecycline discussion with Wyeth (minute 13)
Dr Patricia Bradford PB Associate Director, Discovery Research
Dr Francoise de Cremiers FC Vice-President Regulatory Affairs, Europe, Middle East, Africa
Dr Nathalie Dartois ND Associate Director, Clinical R&D
Dr Evelyn J. Ellis-Grosse EE-G Senior Director, Clinical R&D
Miss Ishwari Kavdikar IK Associate Director, Worldwide Regulatory Affairs
Dr Evan Loh EL Vice-President, Clinical R&D

1 Chairman’s welcome and report
Dr Olga Stetsiouk and Dr Francisco Soriano welcomed as new members representing the EUCAST General Committee. IN-E represented SRGA in place of AO, and C-JS represented CA-SFM in place of FG.

2 Daptomycin breakpoints
Formal assessment of EUCAST breakpoints for daptomycin was started. Following a presentation by Chiron there was detailed discussion and tentative breakpoints were agreed for discussion by national breakpoint committees.

3 Committee membership 2004/2005
Official terms of GK and DB, and national representatives end in April 2005. GK, DB indicated their willingness to continue but alternatives could be proposed to the ESCMID executive. The national representatives should be confirmed by national committees or replacements named.

4 Minutes of meeting of 30 April 2004
Accepted as a correct record with minor modifications.

5 Matters arising from minutes of 30 April 2004
Declarations of interest have been received from almost all Steering Committee members.

Table of comments on proposed breakpoints and Steering Committee responses to be updated.

Steering Committee expenses claims require evidence of travel.

Footnote to glycopeptide breakpoint table modified.
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td><strong>EUCAST documents</strong> Intracellular pathogens and mycobacteria documents to be updated.</td>
</tr>
<tr>
<td>8</td>
<td><strong>NCCLS</strong> GK reported on the June 2004 meeting.</td>
</tr>
<tr>
<td>9</td>
<td><strong>CEN/ISO meeting on 17th September 2004</strong> Draft broth microdilution method should be available by the end of the year. First draft of the document on automated system evaluation has been produced. Possibility of a procedure for antifungals was discussed.</td>
</tr>
<tr>
<td>10</td>
<td><strong>Collaboration with other groups</strong> Collaboration to be pursued with other groups including European Study Group for Sexually Transmitted Infections, a similar group on meningococcal infections and a European Veterinary Group.</td>
</tr>
<tr>
<td>11</td>
<td><strong>Letter on EUCAST breakpoint setting procedures and comments on breakpoints from CA-SFM</strong> This was discussed in detail and responses agreed. GK and DB to offer to attend a CA-SFM meeting.</td>
</tr>
<tr>
<td>12</td>
<td><strong>ECCMID symposium</strong> Details of proposed symposium agreed.</td>
</tr>
<tr>
<td>13</td>
<td><strong>Presentation on tigecycline by Wyeth</strong> There was a preliminary meeting to clarify the requirements of EUCAST before submitting data and requesting breakpoints.</td>
</tr>
<tr>
<td>14</td>
<td><strong>EUCAST workshops 2005</strong> Back-to-back meeting with EARSS in November 2005 was proposed. Half day meeting for National Committee members at the ECCMID meeting in Copenhagen agreed.</td>
</tr>
<tr>
<td>15</td>
<td><strong>Rationale documents</strong> To be developed further.</td>
</tr>
<tr>
<td>16</td>
<td><strong>Carbapenem breakpoints</strong> Preliminary breakpoints discussed.</td>
</tr>
<tr>
<td>17</td>
<td><strong>Any other business</strong> None.</td>
</tr>
</tbody>
</table>

Minutes ratified 22 November 2004